Nicorette Invisi (Nicotine)

Nicotine, the active ingredient in Nicorette Invisi, is a nicotine replacement therapy presented as a transdermal patch for transdermal use. It is intended to help adult smokers reduce withdrawal symptoms and quit tobacco use. GNH USA supplies Nicorette Invisi as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Nicorette Invisi is a nicotine replacement product used within the smoking cessation pathway. - Smoking cessation: helps adult smokers manage cravings and withdraw from tobacco. - Tobacco dependence: provides controlled nicotine delivery to reduce dependence. - Relapse prevention: supports former smokers in maintaining abstinence from cigarettes.

Nicotine patches can cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Skin irritation at the application site - Sleep disturbance or vivid dreams - Headache - Nausea - Dizziness - Mild tachycardia

Serious or Rare Side Effects: - Allergic skin reaction (rash, swelling) - Severe hypertension or arrhythmia - Persistent nausea or vomiting - Chest pain - Severe skin necrosis - Syncope (fainting)

When using Nicorette Invisi, certain precautions should be observed to ensure safety. - Cardiovascular assessment: evaluate patients with recent heart disease before initiating therapy. - Dose selection: start with the lowest effective patch strength. - Concomitant nicotine: avoid using other nicotine products simultaneously. - Pregnancy and lactation: discuss risks with a healthcare professional. - Child safety: keep patches out of reach of children and pets. - Store at room temperature: keep in original packaging, protect from moisture and direct heat.

Nicotine patches may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use of other nicotine replacement products (e.g., gum, lozenges) – risk of nicotine overdose. - Monoamine oxidase inhibitors – may potentiate cardiovascular effects.

Moderate Interactions (Monitor Closely): - Beta‑blockers – nicotine‑induced tachycardia may be masked. - CYP2A6 substrates (e.g., certain antipsychotics) – nicotine may alter metabolism. - Antihypertensive agents – nicotine may reduce their efficacy. - Caffeine – nicotine can increase stimulant effects.